A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)

Inclusion Criteria: * Subject is less than or equal to 75 years of age * Subject is a postmenopausal female * Subject is within 30% of ideal body weight * Subject is judged to be in good health * Subject is a nonsmoker * Subject is willing to avoid excessive alcohol consumption for the duration of the study * Subject is willing to avoid strenuous physical activity for the duration of the study * Subject agrees to refrain from consuming grapefruit or grapefruit juice for the duration of the study Exclusion Criteria: * Subject has a history of multiple/severe allergies to foods or drugs * Subject has had surgery within 12 weeks of starting study or has given blood within 4 weeks of starting study * Subject has a history of major GI abnormalities/ulcers, or genitourinary, cardiovascular, hepatic, pulmonary, psychiatric, endocrine, or metabolic diseases * Subject has a history of bone disease or treatment with bisphosphonates * Subject has an infection/condition that would suppress the immune system, including HIV * Subject has a history of chronic/active hepatic (liver) disease, including Hepatitis B and C * Subject regularly uses illegal drugs * Subject consumes more than 3 alcoholic beverages per day * Subject consumes more than 4 cups of brewed coffee (or equivalent caffeinated beverages) per day * Subject requires use of any prescription or non-prescription medications during the study * Part I only: subject has received treatment with any of the following: any estrogen preparation, anabolic steroids, calcitonin, or progestins within 6 months of study start; thyroid hormone if not on a stable dose; fluoride treatment greater than 1mg/day for more than 2 weeks; Glucocorticoid treatment; Vitamin A greater than 10,000 U/day, vitamin D greater than 2000 U/day, anticonvulsants; selective estrogen receptor modulators within 6 months of study start; parathyroid hormone within 2 years of study start; or bisphosphonates.